mimibibliographie zur frage der behandlung des pruritis mit dem alten kappa agonisten nalbuphin
9370866 1997. Nalbuphine and pruritus
9203908 1997. Nalbuphine and pruritus
30484997 2022. Nalbuphine
| 25885112 2015. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
|
| 31568781 2019. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis
|
| 35497636 2022. Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications
|
| 34576988 2021. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic
|
| 29253847 2017. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus
|
| 29929599 2018. End-Stage Renal Disease Chronic Itch and Its Management
|
20951695 2011. Clonidine inhibits itch-related response through stimulation of alpha(2)-adrenoceptors in the spinal cord in mice
| 30426802 2018. Novel drugs for the treatment of chronic pruritus
|
| 33296031 2022. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans
|
| 25861786 2015. Targeting Itch with Ligands Selective for kappa Opioid Receptors
|
| 34780095 2022. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
|
die meisten papers im perioperativen setting bei opiat-nw, hier nicht dargestellt.
in begrenzter indikation dialysepatienten mit ausschluß anderer ätiologie renalem pruritus demnächst i.v. difelikefalin, andere anwendung in fachinfo höflichs nicht erwünscht.
